ExpreS2ion Biotech Holding AB's ROE % for the quarter that ended in Mar. 2026 was -124.21%. ExpreS2ion Biotech Holding AB's PB Ratio for the quarter that ended in Mar. 2026 was 0.99.
ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -125.46%.
ExpreS2ion Biotech Holding AB ROE % Adjusted to Book Value Related Terms
ExpreS2ion Biotech Holding AB ROE % Adjusted to Book Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB ROE % Adjusted to Book Value Chart
FRA:5JD0 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -125.46% mean?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a ROE % Adjusted to Book Value of -125.46% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value too high?
ExpreS2ion Biotech Holding AB's current ROE % Adjusted to Book Value is -125.46%. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's ROE % Adjusted to Book Value of -125.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current ROE % Adjusted to Book Value is -125.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current ROE % Adjusted to Book Value of -125.46%. The stock's GF Value™ is €0.09, compared to a current price of €0.11 — trading 23.9% above its estimated fair value. The current ROE % Adjusted to Book Value is -125.46%. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current ROE % Adjusted to Book Value is -125.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be overvalued.
The current stock price of €0.11 is trading 23.9% above its estimated GF Value™ of €0.09.
Key valuation signals for FRA:5JD0:
ROE % Adjusted to Book Value: -125.46%
GF Value™: €0.09 vs. price of €0.11 (23.9% above fair value)
No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for FRA:5JD0
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JD0 has been successfully added to your 
